Captor Therapeutics Spolka Akcyjna (CTX.WA) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. CTX.WA files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.64% | 30.00% | Pass |
| Interest-bearing investments | 7.38% | 30.00% | Pass |
| Non-permissible income | 38.97% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.87% | 33.00% | Pass |
| Interest-bearing investments | 80.23% | 33.00% | Fail |
| Non-liquid assets | 19.77% | at least 20.00% | Fail |
| Non-permissible income | 38.97% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.87% | 33.33% | Pass |
| Cash + interest-bearing securities | 80.23% | 33.33% | Fail |
| Accounts receivable | 80.23% | 33.33% | Fail |
| Non-permissible income | 38.97% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 17.87% | 33.33% | Pass |
| Cash + interest-bearing securities | 80.23% | 33.33% | Fail |
| Accounts receivable | 80.23% | 50.00% | Fail |
| Non-permissible income | 38.97% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.13% | 33.00% | Pass |
| Cash + interest-bearing securities | 9.54% | 33.00% | Pass |
| Accounts receivable | 0.00% | 33.00% | Pass |
| Non-permissible income | 38.97% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.95% | 33.00% | Pass |
| Cash + interest-bearing securities | 8.75% | 49.00% | Pass |
| Accounts receivable | 0.00% | 49.00% | Pass |
| Non-permissible income | 38.97% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.95% | 33.33% | Pass |
| Cash + interest-bearing securities | 8.75% | 33.33% | Pass |
| Accounts receivable | 8.75% | 49.00% | Pass |
| Non-permissible income | 38.97% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 54.10 | NEUTRAL |
| Stochastic %K (14) | 87.72 | SELL |
| CCI (20) | 181.41 | SELL |
| Williams %R (14) | -12.28 | SELL |
| MACD (12,26,9) | 0.19 | BUY |
| ROC (10) | 0.41 | BUY |
| Momentum (10) | 0.30 | BUY |
| EMA (10) | 72.06 | BUY |
| SMA (10) | 71.64 | BUY |
| EMA (20) | 72.15 | BUY |
| SMA (20) | 72.03 | BUY |
| EMA (30) | 72.47 | BUY |
| SMA (30) | 72.05 | BUY |
| EMA (50) | 73.24 | BUY |
| SMA (50) | 73.11 | BUY |
| EMA (100) | 73.88 | SELL |
| SMA (100) | 75.57 | SELL |
| EMA (200) | 70.36 | BUY |
| SMA (200) | 76.32 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratitoclax, a bifunctional MCL-1 protein degrader that is in the CTA-enabling stage for liquid and solid tumors; CT-02B, a NEK7 degrader that is in preclinical trials for neuroinflammation indications in Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS); CT-02S, a NEK7 degrader that is in preclinical trials for systemic autoimmunity indications in inflammatory bowel diseases (IBD), gout, and dermatological diseases; and CT-05, a PKCtheta degrader that is in preclinical trials for autoimmunity, transplantation, and metabolism indications. In addition, the company's candidates in the discovery phase include an undisclosed project for oncology, autoimmunity, CNS, and rare indications; and novel E3 ligases for oncology and autoimmunity indications. Captor Therapeutics Spolka Akcyjna was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2022-12-31, figures in PLN.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.
